

## **Certificate of Analysis for NR-46248**

## Staphylococcus aureus, Strain NY-76

## Catalog No. NR-46248

**Product Description**: Staphylococcus aureus (S. aureus), strain NY-76 was isolated in 2005 from an intra-abdominal abscess of an 84-year-old female in New York, USA. S. aureus, strain NY-76 is a clinically-associated methicillin-resistant S. aureus (MRSA) strain.

Lot<sup>1</sup>: 64044909 Manufacturing Date: 18FEB2016

TEST	SPECIFICATIONS	RESULTS
Phenotypic Analysis		
Cellular morphology	Gram-positive cocci	Gram-positive cocci
Colony morphology <sup>2</sup>	Report results	Circular, convex, entire, smooth and
		cream (Figure 1)
Motility (wet mount)	Report results	Non-motile
Hemolysis <sup>2</sup>	Report results	β-hemolytic
Biochemical characterization		
Catalase	Positive	Positive
Coagulase <sup>3</sup>	Report results	Positive
VITEK® 2 Compact (GP card)	≥ 90% probability of being S. aureus	S. aureus (99% probability) <sup>4</sup>
VITEK <sup>®</sup> MS (MALDI-TOF)	Consistent with S. aureus	S. aureus (99.9%)
Antibiotic Susceptibility Profile		
VITEK <sup>®</sup> (AST-GP71 card) <sup>5</sup>		
Beta-lactamase <sup>6</sup>	Report results	Positive
Cefoxitin screen	Report results	Positive
Benzylpenicillin	Report results	Resistant (≥ 0.5 µg/mL)
Oxacillin	Resistant	Resistant (≥ 4 µg/mL)
Gentamicin	Sensitive	Sensitive (≤ 0.5 μg/mL)
Ciprofloxacin	Report results	Resistant (≥ 8 µg/mL)
Levofloxacin	Resistant	Resistant (≥ 8 µg/mL)
Moxifloxacin	Report results	Resistant (= 2µg/mL)
Clindamycin (inducible resistance)	Report results	Negative
Erythromycin	Resistant	Resistant (≥ 8 µg/mL)
Clindamycin Quinupristin/dalfopristin	Report results	Resistant (≥ 8 µg/mL) Sensitive (≤ 0.25 µg/mL)
·	Report results	
Linezolid Daptomycin	Sensitive Sensitive	Sensitive (= 2 µg/mL)
Vancomycin	Sensitive	Sensitive (= 1 µg/mL) Sensitive (≤ 0.5 µg/mL)
Minocycline	Report results	Sensitive (≤ 0.5 µg/mL)
Tetracycline	Sensitive	Sensitive (≤ 0.5 µg/mL)
Tigecycline	Report results	Sensitive (≤ 1 µg/mL) <sup>7</sup>
Nitrofurantoin	Report results	Sensitive (≤ 0.12 µg/mL)
Rifampicin	Sensitive	Sensitive (≤ 16 µg/mL)
Trimethoprim/sulfamethoxazole	Sensitive	Sensitive (≤ 0.5 µg/mL)
Etest <sup>®</sup> antibiotic test strips <sup>8</sup>	Contout	σοποιανό (= το μα/πιε/
Chloramphenicol <sup>9</sup>	Report results	Sensitive (= 8 µg/mL) <sup>10</sup>
Teicoplanin <sup>9</sup>	Report results	Sensitive (= 1 µg/mL)
Genotypic Analysis		
Sequencing of 16S ribosomal RNA gene	≥ 99% sequence identity to <i>S. aureus</i>	99.9% sequence identity to S. aureus
(~ 1460 base pairs)	type strain (GenBank: L37597)	type strain (GenBank: L37597)
( 1100 base pairs)	, , , , , , , , , , , , , , , , , , , ,	,
Purity (post-freeze) <sup>11</sup>	Consistent with expected colony	Consistent with expected colony
	morphology	morphology
Viability (post-freeze) <sup>2</sup>	Growth	Growth

BEI Resources www.beiresources.org E-mail: contact@beiresources.org

Tel: 800-359-7370 Fax: 703-365-2898



SUPPORTING INFECTIOUS DISEASE RESEARCH

## **Certificate of Analysis for NR-46248**

<sup>1</sup>S. aureus, strain NY-76 was deposited to BEI Resources as part of the NARSA collection. NR-46248 was produced by inoculation of the deposited material into Tryptic Soy broth and grown 1 day at 37°C in an aerobic atmosphere. Broth inoculum was added to Tryptic Soy agar with 5% defibrinated sheep blood kolles which were grown 1 day at 37°C in an aerobic atmosphere to produce this lot.

<sup>2</sup>1 day at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood

<sup>3</sup>4 hours at 37°C in rabbit serum with 0.15% EDTA (Coagulase Plasma BBL™ 240827)

<sup>7</sup>MIC Interpretation Guideline: EUCAST Version 4.0 (2014)

<sup>8</sup>1 day at 37°C in an aerobic atmosphere on Mueller Hinton agar

<sup>&</sup>lt;sup>11</sup>Purity of this lot was assessed for 7 days at 37°C in an aerobic atmosphere on Tryptic Soy agar with 5% defibrinated sheep blood.



Figure 1: Colony Morphology

**Date:** 31 MAR 2016

Signature:

**BEI Resources Authentication** 

ATCC®, on behalf of BEI Resources, hereby represents and warrants that the material provided under this certificate has been subjected to the tests and procedures specified and that the results described, along with any other data provided in this certificate, are true and accurate to the best of ATCC®'s knowledge.

ATCC® is a trademark of the American Type Culture Collection.

You are authorized to use this product for research use only. It is not intended for human use.

BEI Resources www.beiresources.org E-mail: contact@beiresources.org
Tel: 800-359-7370

Fax: 703-365-2898

<sup>&</sup>lt;sup>4</sup>Percent probabilities above 90% indicate a close match to the typical biochemical pattern for the given organism, with a percent probability of 99% being a perfect match between the test reaction pattern and the unique biochemical pattern of the given organism or organism group. For additional information, please refer to O'Hara, C.M. and J. M. Miller. "Evaluation of the Vitek 2 ID-GNB Assay for Identification of Members of the Family *Enterobacteriaceae* and Other Nonenteric Gram-Negative Bacilli and Comparison with the Vitek GNI+ Card." J. Clin. Microbiol. 41 (2003): 2096-2101. PubMed: 12734254.

Minimum Inhibitory Concentration (MIC); MIC Interpretation Guideline: CLSI M100-S22 (2012)

<sup>&</sup>lt;sup>6</sup>The production of beta-lactamase was detected using a Cefinase™ Paper Disc (BBL™ 231650).

<sup>&</sup>lt;sup>9</sup>For both chloramphenicol (bioMérieux Etest® 412308) and teicoplanin (bioMérieux Etest® 412459), a MIC ≤ 8 μg/mL is sensitive, a MIC = 16 μg/mL is intermediate and a MIC ≥ 32 μg/mL is resistant.

<sup>&</sup>lt;sup>10</sup>S. aureus, strain NY-12 was deposited as having an intermediate susceptibility to chloramphenicol. Antibiotic susceptibility testing performed in duplicate determined that strain NY-12 is susceptible to chloramphenicol.